Integrated immunogenicity analysis of a tetravalent dengue vaccine up to 4 y after vaccination.

ABSTRACT: Two large pivotal phase III studies demonstrated the efficacy of the tetravalent dengue vaccine (CYD-TDV; Dengvaxia®, Sanofi Pasteur) against all dengue serotypes. Here we present an unprecedented integrated summary of the immunogenicity of CYD-TDV to identify the parameters driving the neutralizing humoral immune response and evolution over time. We summarized the immunogenicity profiles of a 3-dose schedule of CYD-TDV administered 6 months apart across 10 phase II and 6 phase III trials undertaken in dengue endemic and non-endemic countries. Dengue neutralizing antibody titers in sera were determined at centralized laboratories using the 50% plaque reduction neutralization test (PRNT₅₀) at baseline, 28 d after the third dose, and annually thereafter for up to 4 y after the thi

SUBMITTER: Vigne C 

PROVIDER: S-EPMC5612045 | biostudies-literature | 2017 Sep

REPOSITORIES: biostudies-literature